Healthmetryx
Healthmetryx is the premier real-world respiratory data platform transforming healthcare through advanced analytics. Their cutting-edge solution collects, integrates, and analyzes real-world respiratory data to deliver actionable insights across multiple healthcare applications, including population health assessments, occupational health, and clinical research. With a massive data scale aggregating 10.9 quintillion combinations of respiratory and demographic datasets, Healthmetryx leverages powerful cloud analytics and flexible deployment models to provide customized reports and insights. Their innovative approach positions them as a leader in the rapidly expanding IoT healthcare market, which is projected to reach $822 billion by 2032.
Healthmetryx
Healthmetryx is the premier real-world respiratory data platform transforming healthcare through advanced analytics. Their cutting-edge solution collects, integrates, and analyzes real-world respiratory data to deliver actionable insights across multiple healthcare applications, including population health assessments, occupational health, and clinical research. With a massive data scale aggregating 10.9 quintillion combinations of respiratory and demographic datasets, Healthmetryx leverages powerful cloud analytics and flexible deployment models to provide customized reports and insights. Their innovative approach positions them as a leader in the rapidly expanding IoT healthcare market, which is projected to reach $822 billion by 2032.
TL;DR
Focus: Respiratory real-world data platform using wearables and AI
Founded: 2020
Headquarters: Boston, MA (office in Montreal, QC)
Flagship device: Clarinet wearable
Funding status: Pre-Seed round announced Jul 20, 2020; amount undisclosed
Company Overview
Problem Domain
Respiratory health monitoring, population health analytics, decentralized clinical research, and occupational/workforce health.
Founded
2020
Industry
Health technology / Digital health
Tech Stack
Funding Track Record
One funding round recorded on Jul 20, 2020; amount and investors not disclosed